500 related articles for article (PubMed ID: 17983836)
1. In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression.
Villaron EM; Almeida J; Lopez-Holgado N; Sanchez-Guijo FM; Alberca M; Blanco B; Sanchez-Abarca LI; Lopez O; Perez-Simon JA; San Miguel JF; del Cañizo MC
Transfus Apher Sci; 2007 Oct; 37(2):145-56. PubMed ID: 17983836
[TBL] [Abstract][Full Text] [Related]
2. Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens.
Bender JG; Lum L; Unverzagt KL; Lee W; Van Epps D; George S; Coon J; Ghalie R; McLeod B; Kaizer H
Bone Marrow Transplant; 1994 Apr; 13(4):479-85. PubMed ID: 7517260
[TBL] [Abstract][Full Text] [Related]
3. [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
Klabusay M; Lysák D; Hrabcáková V; Navrátil M; Coupek P; Mayer J
Cas Lek Cesk; 2008; 147(6):319-24. PubMed ID: 18724529
[TBL] [Abstract][Full Text] [Related]
4. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
[TBL] [Abstract][Full Text] [Related]
5. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.
Shapiro F; Yao TJ; Moskowitz C; Reich L; Wuest DL; Heimfeld S; McNiece IK; Gabrilove J; Nimer S; Moore MA
Clin Cancer Res; 1997 Sep; 3(9):1571-8. PubMed ID: 9815845
[TBL] [Abstract][Full Text] [Related]
6. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
[TBL] [Abstract][Full Text] [Related]
7. Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts.
Theilgaard-Mönch K; Raaschou-Jensen K; Andersen H; Russell CA; Vindeløv L; Jacobsen N; Dickmeiss E
Bone Marrow Transplant; 1999 Feb; 23(3):243-9. PubMed ID: 10084255
[TBL] [Abstract][Full Text] [Related]
8. Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both.
Ho AD; Young D; Maruyama M; Corringham RE; Mason JR; Thompson P; Grenier K; Law P; Terstappen LW; Lane T
Exp Hematol; 1996 Nov; 24(13):1460-8. PubMed ID: 8950228
[TBL] [Abstract][Full Text] [Related]
9. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis.
Zeller W; Gutensohn K; Stockschläder M; Dierlamm J; Kröger N; Koehne G; Hummel K; Kabisch H; Weh HJ; Kühnl P; Hossfeld DK; Zander AR
Bone Marrow Transplant; 1996 May; 17(5):709-13. PubMed ID: 8733686
[TBL] [Abstract][Full Text] [Related]
10. Separation of chemotherapy plus G-CSF-mobilized peripheral blood mononuclear cells by counterflow centrifugal elutriation: in vitro characterization of two different CD34+ cell populations.
Teofili L; Rutella S; Pierelli L; Ortu la Barbera E; Di Mario A; Menichella G; Rumi C; Leone G
Bone Marrow Transplant; 1996 Aug; 18(2):421-5. PubMed ID: 8864456
[TBL] [Abstract][Full Text] [Related]
11. The composition of CD34 subpopulations differs between bone marrow, blood and cord blood.
Fritsch G; Stimpfl M; Kurz M; Printz D; Buchinger P; Fischmeister G; Hoecker P; Gadner H
Bone Marrow Transplant; 1996 Feb; 17(2):169-78. PubMed ID: 8640162
[TBL] [Abstract][Full Text] [Related]
12. Characterization and quantitation of primitive hematopoietic progenitor cells present in peripheral blood autografts.
Tong J; Hoffman R; Siena S; Srour EF; Bregni M; Gianni AM
Exp Hematol; 1994 Sep; 22(10):1016-24. PubMed ID: 8088376
[TBL] [Abstract][Full Text] [Related]
13. Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma.
de Bont ES; Guikema JE; Scherpen F; Meeuwsen T; Kamps WA; Vellenga E; Bos NA
Cancer Res; 2001 Oct; 61(20):7654-9. PubMed ID: 11606408
[TBL] [Abstract][Full Text] [Related]
14. Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Zeller W; Kröger N; Berger J; Krueger W; Dierlamm J; Stockschläder M; Gutensohn K; Hossfeld DK; Zander AR
J Hematother Stem Cell Res; 1999 Oct; 8(5):539-46. PubMed ID: 10791904
[TBL] [Abstract][Full Text] [Related]
15. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
[TBL] [Abstract][Full Text] [Related]
18. Correlations between hematopoietic progenitor cell counts as measured by Sysmex and CD34+ cell harvest yields following mobilization with different regimens.
Vogel W; Kopp HG; Kanz L; Einsele H
J Cancer Res Clin Oncol; 2002 Jul; 128(7):380-4. PubMed ID: 12136252
[TBL] [Abstract][Full Text] [Related]
19. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.
Glück S; Ross AA; Layton TJ; Ostrander AB; Goldstein LC; Porter K; Ho AD
Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299
[TBL] [Abstract][Full Text] [Related]
20. The CXCL12-3'A allele is associated with a higher mobilization yield of CD34 progenitors to the peripheral blood of healthy donors for allogeneic transplantation.
Bogunia-Kubik K; Gieryng A; Dlubek D; Lange A
Bone Marrow Transplant; 2009 Sep; 44(5):273-8. PubMed ID: 19252530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
